Leap Therapeutics to present updated DKN-01/Gastric Cancer data at ASCO 2023

CYPHERPUNK TECHNOLOGIES INC.

Will present long-term follow-up data from Part A of Phase 2 DisTinGuish study at ASCO June 2-6, 2023.
Presentation scheduled for June 5, 2023, at 11:30 a.m. ET; abstract #4027, poster discussion session.
Study combines DKN-01 (anti-DKK1) + tislelizumab + chemo in first-line advanced GEA; Part A enrolled 25 pts.
Ongoing Part C enrolling ~160 first-line HER2- GEA pts in randomized controlled trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.